International Journal of Community Medicine and Public Health
Carrizales SH et al. Int J Community Med Public Health. 2024 Oct;11(10):4085-4088
http://www.ijcmph.com
pISSN 2394-6032 | eISSN 2394-6040

DOI: https://dx.doi.org/10.18203/2394-6040.ijcmph20242685

Review Article

Cardiovascular risk in individuals with kidney disease

Selene H. Carrizales[1]*, Belen Domingo Cruz Hernandez Egresado[2], Itzel B. C. Pineda[3], Paulina G. Valladares[4], Jose R. R. Castellares[3], Mariana G. M. Velázquez[5], Manuel A. V. Villegas[6], Siomara E. L. Ruiz[7], Ulises S. Bermudez[8], Adriana C. Aguilar[9]

[1]Clinica Hospital Constitucion, ISSSTE, Monterrey, Nuevo León, Mexico
[2]Universidad Xochicalco, Ensenada, B.C., Mexico
[3]Universidad Autónoma de Baja California, Baja California, Mexico
[4]Universidad de Guadalajara, Guadalajara, Mexico
[5]Hospital General de Zona No. 32 "Dr. Mario Navarro Madrazo", IMSS, CDMX, Mexico
[6]Hospital Regional Dr. Valentín Gómez Farías, Zapopan, Mexico
[7]Universidad Autónoma de Guadalajara, Guadalajara, Mexico
[8]Hidra Centro de Investigación, Mexico
[9]Hospital General Ensenada/Universidad Autónoma de Guadalajara, Guadalajara, Mexico

Received: 24 August 2024
Revised: 28 August 2024
Accepted: 09 September 2024

***Correspondence:**
Dr. Selene H. Carrizales,
E-mail: selene99@gmail.com

ABSTRACT

The worldwide prevalence of chronic kidney disease (CKD) is estimated to exceed 700 million persons, with the incidence steadily increasing due to factors such as an aging population and the growing prevalence of chronic diseases such as diabetes and hypertension. Cardiovascular disease is the primary cause of illness and mortality in persons with nephropathy. Effectively treating nephropathy and cardiovascular risk in individuals with kidney disease is a major challenge in clinical practice. Every patient requires a comprehensive assessment and tailored therapy. In order to reduce the likelihood of cardiovascular events in patients with nephropathy, it is necessary to avoid and rapidly address cardiovascular risk factors. In order to enhance the overall well-being and longevity of individuals with kidney disease, it is essential to identify and address any cardiovascular issues.

Keywords: Cardiovascular disease, Kidney disease, Epidemiology

INTRODUCTION

Chronic kidney disease (CKD) is a widespread clinical disorder that affects millions of people worldwide. The worldwide prevalence of CKD is estimated to exceed 700 million persons, with the incidence increasing due to the aging population and the prevalence of chronic diseases such as diabetes and hypertension. Nephropathy may be caused by a variety of disorders, such as diabetes, hypertension, autoimmune problems, and infections.[1]

Cardiovascular disease is the primary cause of illness and mortality among people with nephropathy. Patients with nephropathy have an increased likelihood of developing peripheral vascular disease, cerebrovascular disease, and coronary heart disease. The relationship between these two parameters is intricately linked and influenced by several cardiovascular risk factors, including hypertension, dyslipidemia, chronic inflammation, and endothelial dysfunction.[2]

In order to lessen the number of fatalities and illnesses that are caused by cardiovascular conditions and to enhance the general well-being of patients who have nephropathy, it is essential to appropriately assess and treat the risk factors that are associated with cardiovascular disease. When it comes to slowing the course of renal disease and minimizing the risk of cardiovascular disease in patients who have nephropathy, the early recognition of cardiovascular risk factors and the implementation of suitable therapies are of such critical importance.[3]

The purpose of this literature review article is to discuss the most important aspects of cardiovascular risk in individuals who have nephropathy. These aspects include the epidemiology of the condition, its clinical importance, cardiovascular pathophysiology, screening tools, treatment options, and related outcomes. According to the guidelines that are currently in place, the primary emphasis will be on emphasizing the most recent discoveries that have been published in the medical literature in order to provide guidance for the management of cardiovascular risk in patients who have nephropathy.

Pathophysiology

Various pathological changes associated with nephropathy increase the likelihood of cardiovascular disease in affected persons. Besides proteinuria, a reduction in glomerular filtration rate (GFR) may lead to endothelial dysfunction, chronic inflammation, and activation of the renin-angiotensin-aldosterone system (RAAS). Endothelial dysfunction leads to a decrease in nitric oxide production and an increase in the generation of reactive oxygen species, hence accelerating the progression of atherosclerosis. Nephropathy patients often experience chronic inflammation, which is caused by the activation of inflammatory cells and the production of pro-inflammatory cytokines. The activation of the RAAS system induces vasoconstriction, salt retention, and the production of the hormone aldosterone. This activation also leads to arterial hypertension and ventricular dysfunction.[4]

Examination

It is crucial to thoroughly evaluate the cardiovascular risk of patients with nephropathy in order to promptly identify risk factors and execute appropriate therapies. As per current guidelines, it is recommended that all patients with CKD have an evaluation of their cardiovascular risk factors. The risk factors are hypertension, dyslipidemia, diabetes mellitus, smoking, and obesity. Furthermore, it is recommended that individuals with risk factors or symptoms of cardiovascular illness have an assessment for coronary heart disease.[5]

Identifying and controlling cardiovascular risk factors, such as high blood pressure, abnormal levels of fats in the blood, diabetes, and smoking, are crucial for managing the risk of cardiovascular disease in individuals with kidney disease. Antihypertensive drugs that inhibit the RAAS, such as angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor antagonists (ARBs), are recommended for the treatment of individuals with nephropathy due to their proven ability to reduce the likelihood of cardiovascular disease. For diabetes mellitus patients, it is recommended to carefully regulate glycemic levels in order to reduce the risk of cardiovascular complications.[6]



Figure 1: Risk factors.[7]

Nephropathy patients are more prone to cardiovascular disorders, including coronary heart disease, cerebrovascular disease, peripheral vascular disease, and heart failure. Coronary heart disease is the most common cardiovascular complication in patients with nephropathy. It is associated with an increased incidence of atherosclerosis, impaired function of the endothelium, and chronic inflammation in these people. Additional common outcomes seen in individuals with nephropathy include cerebral and peripheral vascular disease, which are

associated with atherosclerosis and endothelial dysfunction. Individuals suffering with nephropathy have the potential to develop heart failure, a medical disease that is associated with ventricular dysfunction and unregulated hypertension. Early identification of risk factors and appropriate therapies are essential for managing cardiovascular issues in individuals with nephropathy. In order to reduce the likelihood of cardiovascular events, it is recommended that persons diagnosed with coronary heart disease undergo treatment with antiplatelet medicines and/or statins. Diuretics, ACE inhibitors, ARBs, and beta-blockers are prescribed for heart failure patients due to their shown efficacy in reducing death rates and alleviating symptoms.[6]

DISCUSSION

Nephropathy is a serious ailment that tends to develop as a consequence of chronic disorders such as diabetes, hypertension, and others. As a result of the many risk factors and pathophysiological changes that are linked with kidney disease, patients who have nephropathy are at an increased risk of developing cardiovascular disease. To reduce the possibility of cardiovascular events occurring in these individuals, it is necessary to carry out a comprehensive evaluation of cardiovascular risk and to treat risk factors in an efficient manner.[7]

The presence of elevated blood pressure is a crucial factor that contributes to the development of nephropathy in persons. The ability to effectively manage one's blood pressure has been shown to minimize the chance of cardiovascular events occurring in those who suffer from nephropathy. In order to reduce the risk of cardiovascular events, those who are afflicted with renal sickness should make it a priority to keep their blood pressure at or below 130/80 mmHg.[9]

Dyslipidemia is a significant additional risk factor that is present in individuals who have nephropathy. It is possible that the kidneys' diminished ability to remove lipids is the cause of dyslipidemia, which is a disorder that is common in patients who have nephropathy. Statin treatment has been demonstrated to reduce the risk of cardiovascular events in patients who are suffering from renal sickness, according to the available evidence. It is suggested that those who suffer from nephropathy and coronary heart disease take statin medicine in order to lessen the probability of experiencing cardiovascular events.[9] When it comes to those who have nephropathy, anemia is often linked to an elevated risk of developing cardiovascular disease. People who suffer from nephropathy and anemia may experience an improvement in their quality of life and a reduction in their risk of cardiovascular disease if they are given medications that stimulate erythropoiesis.[8,9]

Nephropathy patients often die from cardiovascular disease, which is the leading cause of mortality in this population. Nephropathy patients have a greater risk of developing cerebrovascular accidents, heart failure, and coronary heart disease than those who do not have the condition. People who have nephropathy are most likely to have coronary heart disease, which is the most prevalent cardiovascular problem. Due to the existence of a number of risk factors, patients who have nephropathy have a greater incidence of coronary heart disease. These risk factors include high blood pressure, dyslipidemia, and diabetes.[1-3]

People who have nephropathy are more likely to get heart failure, which is a cardiovascular problem. Individuals who have nephropathy are more likely to have heart failure due to the presence of a number of risk factors, including high blood pressure, anemia, and coronary heart disease. When it comes to the therapy of heart failure in individuals who have nephropathy, diuretics, ACE inhibitors, ARBs, and beta-blockers are all very important medications. It has been shown that these drugs may both lower death rates and improve symptoms in the patients in question.[4]

			Albuminuria categories (mg/g)			
			A1		A2	A3
			<10 mg/g	10-29 mg/g	30–299 mg/g	≥300 mg/g
GFR categories (ml/min/1.73 m²)	G1	≥105	0.93 (0.74–1.16)	1.33 (1.04–1.72)	2.46 (1.88–3.23)	2.69 (1.36–5.32)
		90–104	1 (reference)	1.63 (1.20–2.19)	1.82 (1.36–2.45)	4.77 (3.16–7.22)
	G2	75–89	1.03 (0.85–1.24)	1.48 (1.23–1.78)	1.73 (1.29–2.32)	4.01 (2.62–6.14)
		60–74	1.09 (0.92–1.29)	1.58 (1.31–1.91)	2.18 (1.58–3.02)	4.23 (2.95–6.06)
	G3a	45–59	1.52 (1.18–1.97)	2.38 (1.91–2.96)	3.13 (2.32–4.22)	4.97 (3.70–6.66)
	G3b	30–44	2.40 (1.80–3.21)	3.07 (1.73–5.44)	4.12 (2.84–5.98)	6.10 (4.08–9.10)
	G4	15–29	13.51 (4.89–37.35)	7.99 (1.95–32.81)	5.60 (3.66–8.57)	9.49 (4.97–18.10)
	G5	<15				

Figure 2: CVD mortality risk across CKD categories.[6]

CONCLUSION

Nephropathy is a common and significant consequence that often arises as a result of chronic diseases such as diabetes, hypertension, and another kind of chronic sickness. As a result of the many risk factors and pathophysiological changes that are linked with kidney disease, patients who have nephropathy are at an increased risk of developing cardiovascular disease. To reduce the possibility of cardiovascular events occurring in these individuals, it is necessary to carry out a comprehensive evaluation of cardiovascular risk and to treat risk factors in an efficient manner. When it comes to the treatment of nephropathy, it is very necessary to take care of risk factors including hypertension, dyslipidemia, and anemia. Furthermore, these patients often suffer from heart failure and coronary heart disease, both of which need to be well controlled in order to lessen the probability of these patients experiencing cardiovascular events.

In clinical practice, one of the most significant challenges is the care of nephropathy and cardiovascular risk in patients who have nephropathy. A thorough evaluation and individualized treatment plan are necessities for each and every patient. It is vital to minimize cardiovascular risk factors and to treat them as soon as possible in order to reduce the possibility of cardiovascular events occurring in individuals who have nephropathy. It is vital to detect and treat any cardiovascular abnormalities that may be present in persons who have renal disease in order to improve their general well-being and increase their lifespan.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circ Res. 2023;132(8):1050-63.
2. Li X, Lindholm B. Cardiovascular risk prediction in chronic kidney disease. Am J Nephrol. 2023;53(10):730-9.
3. Scilletta S, Di Marco M, Miano N, Filippello A, Di Mauro S, Scamporrino A, et al. Update on diabetic kidney disease (DKD): focus on non-albuminuric DKD and cardiovascular risk. Biomolecules. 2023;13(5):752.
4. Schuett K, Marx N, Lehrke M. The cardio-kidney patient: epidemiology, clinical characteristics and therapy. Circ Res. 2023;132(8):902-14.
5. Laville SM, Couturier A, Lambert O, Metzger M, Mansencal N, Jacquelinet C, et al. Urea levels and cardiovascular disease in patients with chronic kidney disease. Nephrol Dialysis Transplantat. 2023;38(1):184-92.
6. Kanbay M, Copur S, Siriopol D, Yildiz AB, Berkkan M, Tuttle KR, et al. The risk for chronic kidney disease in metabolically healthy obese patients: a systematic review and meta-analysis. Eur J Clin Investig. 2023;53(1):e13878.
7. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606-35.
8. Mainieri F, La Bella S, Chiarelli F. Hyperlipidemia and cardiovascular risk in children and adolescents. Biomedicines. 2023;11(3):809.
9. Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273-85.

Cite this article as: Carrizales SH, Egresado BDCH, Pineda IBC, Valladares PG, Castellares JRR, Velázquez MGM, et al. Cardiovascular risk in individuals with kidney disease. Int J Community Med Public Health 2024;11:4085-8.